Format

Send to

Choose Destination
Arch Ophthalmol. 2008 Aug;126(8):1030-6. doi: 10.1001/archopht.126.8.1030.

Canadian Glaucoma Study: 2. risk factors for the progression of open-angle glaucoma.

Author information

1
Department of Ophthalmology and Visual Sciences, Dalhousie University, Second Floor, Centennial Bldg, Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada B3H 2Y9. bal@dal.ca

Erratum in

  • Arch Ophthalmol. 2008 Oct;126(10):1364.

Abstract

OBJECTIVE:

To determine systemic and ocular risk factors for visual field progression in open-angle glaucoma.

METHODS:

In the Canadian Glaucoma Study, a multicenter prospective longitudinal study of 258 patients (131 men and 127 women; median age, 65.0 years), baseline systemic measures included assessment of peripheral vasospasm and markers for hematopathology, coagulopathy, and immunopathology. Patients were followed up at 4-month intervals with perimetry, optic disc imaging, and a standardized interventional protocol for intraocular pressure control. Univariate and proportional hazards models were used to identify factors that predicted progression.

MAIN OUTCOME MEASURE:

Visual field progression with standard automated perimetry.

RESULTS:

Median follow-up was 5.3 years, with 167 patients (64.7%) completing 5 years or more and 67 patients (26.0%) completing 7 years or more. Abnormal baseline anticardiolipin antibody levels (hazard ratio [HR], 3.86; 95% confidence interval [CI], 1.60-9.31), higher baseline age (HR per year, 1.04; 95% CI, 1.01-1.07), female sex (HR, 1.94; 95% CI, 1.09-3.46), and higher mean follow-up intraocular pressure (HR per 1 mm Hg, 1.19; 95% CI, 1.05-1.36) before progression were associated with progression.

CONCLUSIONS:

The Canadian Glaucoma Study identified 4 independent predictive factors for glaucomatous field progression. Application to Clinical Practice While confirming the importance of intraocular pressure in glaucoma progression, this study determined other risk factors that merit awareness.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00262626.

Comment in

PMID:
18695095
DOI:
10.1001/archopht.126.8.1030
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center